The FDA issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products sold online26
Companies were accused of implying their compounded products are the same as FDA-approved medicines and obscuring product sourcing through branded advertising without qualification26
Primary violations included claims stating compounded drugs have the same active ingredients as FDA-approved drugs, claims implying equivalence, claims of clinical efficacy, and implications of FDA approval3
In one case involving GenoGenix, the FDA documented three emergency room visits after patients took a NAD+ product compounded by the pharmacy, with patients experiencing low blood pressure, uncontrollable shaking, and other symptoms2
The FDA found manufacturing violations at some compounding facilities including unsanitary conditions, operator errors, and infrastructure issues that could compromise product integrity2
Compounded GLP-1s became prevalent as patients struggled to access or afford branded products from Novo Nordisk and Eli Lilly, with Novo estimating 1 million people were taking compounded GLP-1 medicines last year2
The FDA action is part of a broader crackdown announced in February 2026 that includes restricting GLP-1 active pharmaceutical ingredients in unapproved compounded products and enforcement against misleading advertising3
Sources:
2. https://www.biospace.com/fda/fda-sends-30-warning-letters-to-continue-clampdown-on-compounded-glp-1s
3. http://www.mcdermottplus.com/insights/fdas-makary-declares-upcoming-crackdown-on-glp-1-claims-importation/
6. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s